Anifrolumab Pregnancy Study

Exclusion Criteria

• •\- Pregnancies whose date of conception cannot be established
• •Women treated with anifrolumab during pregnancy and/or 16-week period prior to LMP2
• •Pregnancies whose date of conception cannot be established
• •Women with a history of CM or chromosomal abnormalities (according to available records), before delivery
• •Women prescribed a confirmed teratogenic drug prior to LMP2 with a time period of 5-half-lives of relevant drug or during pregnancy